Efficacy of biological agents in metastatic triple-negative breast cancer

Cancer Treatment Reviews

Volumn 40, Issue 5, 2014, Pages 605-613

  Bramati, Annalisa ^a   Girelli, Serena ^a   Torri, Valter ^b   Farina, Gabriella ^a   Galfrascoli, Elena ^a   Piva, Sheila ^a   Moretti, Anna ^a   Dazzani, Maria Chiara ^a   Sburlati, Paola ^a   La Verde, Nicla Maria ^a  

^a Department of Oncology Fatebenefratelli e Oftalmico ^*  (Italy)

^b MARIO NEGRI INSTITUTE FOR PHARMACOLOGICAL RESEARCH   (Italy)

Author keywords

Bevacizumab; Biological agents (BA); Metastatic triple negative breast cancer (mTNBC)

Indexed keywords

ANTHRACYCLINE; BEVACIZUMAB; BIOLOGICAL PRODUCT; CAPECITABINE; CARBOPLATIN; CETUXIMAB; CISPLATIN; DOCETAXEL; GEMCITABINE; INIPARIB; LAPATINIB; PACLITAXEL; SORAFENIB; SUNITINIB;

BREAST METASTASIS; CANCER COMBINATION CHEMOTHERAPY; CHEMOTHERAPY; COST EFFECTIVENESS ANALYSIS; DRUG EFFICACY; HUMAN; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PHASE 3 CLINICAL TRIAL (TOPIC); PROGRESSION FREE SURVIVAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; RISK FACTOR; RISK REDUCTION; SYSTEMATIC REVIEW; TRIPLE NEGATIVE BREAST CANCER;

BEVACIZUMAB; BIOLOGICAL AGENTS (BA); METASTATIC TRIPLE-NEGATIVE BREAST CANCER (MTNBC);

ADULT; AGED; ANTIBODIES, MONOCLONAL, HUMANIZED; DISEASE-FREE SURVIVAL; FEMALE; HUMANS; MIDDLE AGED; NEOPLASM INVASIVENESS; NEOPLASM METASTASIS; NEOPLASM STAGING; NEOVASCULARIZATION, PATHOLOGIC; PROGNOSIS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RECEPTOR, ERBB-2; RISK ASSESSMENT; SURVIVAL ANALYSIS; TREATMENT OUTCOME; TRIPLE NEGATIVE BREAST NEOPLASMS;

EID: 84898488044     PISSN: 03057372     EISSN: 15321967     Source Type: Journal    
DOI: 10.1016/j.ctrv.2014.01.003     Document Type: Review

References (42)

1. Brenton J.D., Carey L.A., Ahmed A.A., Caldas C. Molecular classification and molecular forecasting of breast cancer: ready for clinical application?. J Clin Oncol 2005, 23:7350-7360.
2. Perou C.M., Sørlie T., Eisen M.B., et al. Molecular portraits of human breast tumours. Nature 2000, 406:747-752.
3. Sotiriou C., Neo S.Y., McShane L.M., et al. Breast cancer classification and prognosis based on gene expression profiles from a population-based study. Proc Natl Acad Sci USA 2003, 100:10393-10398.
4. Conforti R., Bidard F.-C., Michiels S., Boulet T., Tomasic G., Mathieu M.-C. Discrepancy between triple negative phenotype and basallike tumor: an immunohistochemical analysis based on 150 "triple-negative" breast cancers. Breast Cancer Res Treat 2007, 106:S135.
5. Nielsen T.O., Hsu F.D., Jensen K., et al. Immunohistochemical and clinical characterization of the basal-like subtype of invasive breast carcinoma. Clin Cancer Res 2004, 10:5367-5374.
6. Cheang M.C., Voduc D., Bajdik C., et al. Basal-like breast cancer defined by five biomarkers has superior prognostic value than triple-negative phenotype. Clin Cancer Res 2008, 14:1368-1376.
7. Bauer K.R., Brown M., Cress R.D., Parise C.A., Caggiano V. Descriptive analysis of estrogen receptor (ER)-negative, progesterone receptor (PR)-negative, and HER2-negative invasive breast cancer, the so-called triple-negative phenotype: a population-based study from the California cancer Registry. Cancer 2007, 109:1721-1728.
8. Kreike B., van Kouwenhove M., Horlings H., et al. Gene expression profiling and histopathological characterization of triple-negative/basal-like breast carcinomas. Breast Cancer Res 2007, 9:R65.
9. Staudacher L., Cottu P.H., Diéras V., et al. Platinum-based chemotherapy in metastatic triple-negative breast cancer: the Institut Curie experience. Ann Oncol 2011, 4:848-856. Epub 2010 October 5.
10. Silver D.P., Richardson A.L., Eklund A.C., et al. Efficacy of neoadjuvant Cisplatin in triple-negative breast cancer. J Clin Oncol 2010, 28:1145-1153.
11. Baselga J., Zambetti M., Llombart-Cussac A., et al. Phase II genomics study of ixabepilone as neoadjuvant treatment for breast cancer. J Clin Oncol 2009, 27:526-534.
12. Iglehart J.D., Silver D.P. Synthetic lethality-a new direction in cancer-drug development. N Engl J Med 2009, 36:189-191.
13. Ferrara N., Davis-Smyth T. The biology of vascular endothelial growth factor. Endocrinol Rev 1997, 18:4-25.
14. Motzer R.J., Rini B.I., Bukowski R.M., et al. Sunitinib in patients with metastatic renal cell carcinoma. JAMA 2006, 295:2516-2524.
15. Escudier B. Sorafenib for the management of advanced renal cell carcinoma. Expert Rev Anticancer Ther 2011, 11:825-836.
16. Escudier B., Eisen T., Stadler W.M., et al. Sorafenib in advanced clear-cell renal-cell carcinoma. N Engl J Med 2007, 356:125-134.
17. Dal Lago L., D'Hondt V., Awada A. Selected combination therapy with sorafenib: A review of clinical data and perspectives in advanced solid tumors. Oncologist 2008, 13:845-858.
18. Goswami S., Sahai E., Wyckoff J.B., et al. Macrophages promote the invasion of breast carcinoma cells via a colony-stimulating factor-1/epidermal growth factor paracrine loop. Cancer Res 2005, 65:5278-5283.
19. Abrams T.J., Murray L.J., Pesenti E., et al. Preclinical evaluation of the tyrosine kinase inhibitor SU11248 as a single agent and in combination with "standard of care" therapeutic agents for the treatment of breast cancer. Mol Cancer Ther 2003, 2:1011-1021.
20. Corkery B., Crown J., Clynes M., et al. Epidermal growth factor receptor as a potential therapeutic target in triple-negative breast cancer. Ann Oncol 2009, 20:862-867.
21. Parmar M.K., Torri V., Stewart L. Extracting summary statistics to perform meta-analyses of the published literature for survival endpoints. Stat Med 1998, 17:2815-2834.
22. Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011] 2011, The Cochrane Collaboration, Available from www.cochrane-handbook.org. J.P.T. Higgins, S. Green (Eds.).
23. Bernsdorf M., Ingvar C., Jörgensen L., et al. Effect of adding gefitinib to neoadjuvant chemotherapy in estrogen receptor negative early breast cancer in a randomized phase II trial. Breast Cancer Res Treat 2011, 126:463-470.
24. Gray R., Bhattacharya S., Bowden C., Miller K., Comis R.L. Independent review of E2100: a phase III trial of bevacizumab plus paclitaxel versus paclitaxel in women with metastatic breast cancer. J Clin Oncol 2009, 27:4966-4972.
25. Di Leo A., Gomez H.L., Aziz Z., et al. Phase III, double-blind, randomized study comparing lapatinib plus paclitaxel with placebo plus paclitaxel as first-line treatment for metastatic breast cancer. J Clin Oncol 2008, 26:5544-5552.
26. Miller K., Wang M., Gralow J., et al. Paclitaxel plus bevacizumab versus paclitaxel alone for metastatic breast cancer. N Engl J Med 2007, 357:2666-2676.
27. Finn R.S., Press M.F., Dering J., et al. Estrogen receptor, progesterone receptor, human epidermal growth factor receptor 2 (HER2), and epidermal growth factor receptor expression and benefit from lapatinib in a randomized trial of paclitaxel with lapatinib or placebo as first-line treatment in HER2-negative or unknown metastatic breast cancer. J Clin Oncol 2009, 27:3908-3915.
28. Miles D.W., Chan A., Dirix L.Y., et al. Phase III study of bevacizumab plus docetaxel compared with placebo plus docetaxel for the first-line treatment of human epidermal growth factor receptor 2-negative metastatic breast cancer. J Clin Oncol 2010, 28:3239-3247.
29. Robert N.J., Diéras V., Glaspy J., et al. RIBBON-1: randomized, double-blind, placebo-controlled, phase III trial of chemotherapy with or without bevacizumab for first-line treatment of human epidermal growth factor receptor 2-negative, locally recurrent or metastatic breast cancer. J Clin Oncol 2011, 29:1252-1260.
30. Brufsky A.M., Hurvitz S., Perez E., Swamy R., Valero V., O'Neill V., et al. RIBBON-2: a randomized, double-blind, placebo-controlled, phase III trial evaluating the efficacy and safety of bevacizumab in combination with chemotherapy for second-line treatment of human epidermal growth factor receptor 2-negative metastatic breast cancer. J Clin Oncol. 2011, 32:4286-4293. Epub 2011 October 11.
31. O'Shaughnessy J., Osborne C., Pippen J.E., et al. Iniparib plus chemotherapy in metastatic triple-negative breast cancer. N Engl J Med 2011, 364:205-214.
32. Bergh J., Bondarenko I.M., Lichinitser M.R., Liljegren A., Greil R., Voytko N.L. First-line treatment of advanced breast cancer with sunitinib in combination with docetaxel versus docetaxel alone: results of a prospective, randomized phase III study. J Clin Oncol 2012, 30:921-929. Epub 2012 Feb 13.
33. Baselga J., Segalla J.G., Roché H., Del Giglio A., Pinczowski H., Ciruelos E.M. Sorafenib in combination with capecitabine: an oral regimen for patients with HER2-negative locally advanced or metastatic breast cancer. J Clin Oncol 2012, 30:1484-1491. Epub 2012 March 12.
34. Baselga J., Gómez P., Greil R., Braga S., Climent M.A., Wardley A.M. Randomized phase II study of the anti-epidermal growth factor receptor monoclonal antibody cetuximab with cisplatin versus cisplatin alone in patients with metastatic triple-negative breast cancer. J Clin Oncol 2013, June 3 [Epub ahead of print].
35. Curigliano G, Pivot X, Cortes J, et al. A randomized phase II study of sunitinib vs standard of care for patients with previously treated advanced triple-negative breast cancer. Poster session 6: Treatment-Advanced disease: Advanced Therapy, SABCS; 2010.
36. Curigliano G., Pivot X., Cortés J., et al. Randomized phase II study of sunitinib versus standard of care for patients with previously treated advanced triple-negative breast cancer. Breast 2013, 22:650-656.
37. Rossari J.R., Metzger-Filho O., Paesmans M., et al. Bevacizumab and Breast Cancer: a meta-analysis of first-line phase iii studies and a critical reappraisal of available evidence. J Oncol 2012, 2012:417673.
38. Broglio K.R., Berry D.A. Detecting an overall survival benefit that is derived from progression-free survival. J Natl Cancer Inst. 2009, 101:1642-1649.
39. D'Agostino R.B. Changing end points in breast-cancer drug approval-the Avastin story. N Engl J Med 2011, 365:e2.
40. Carpenter D., Kesselheim A.S., Joffe S. Reputation and precedent in the bevacizumab decision. N Engl J Med 2011, 365:e3.
41. O'Shaughnessy J, Schwartzberg LS, Danso MA, et al. A randomized phase III study of iniparib (BSI-201) in combination with gemcitabine/carboplatin (G/C) in metastatic triple-negative breast cancer (TNBC). Oral abstract session, breast cancer. ASCO 2011; abstract 1007, J Clin Oncol 2011;29.
42. Lehmann B.D., Bauer J.A., Chen X., et al. Identification of human triple-negative breast cancer subtypes and preclinical models for selection of targeted therapies. J Clin Invest 2011, 121:2750-2767.